SABCS 2026

The 2026 programme spans experimental biology, etiology, translational science, prevention, early detection, treatment and survivorship, including AI-based pathology, cancer prevention vaccines, circulating tumour DNA, radioligand therapies and new treatment approaches. The scientific programme combines formal lectures by experts in clinical, translational and basic research with selected oral and poster presentations, forums and case discussions, alongside award lectures, early-career sessions and patient advocate programmes. It is aimed at physicians and researchers in medical, surgical, gynaecologic and radiation oncology, patient advocates and other health professionals, with more than 10,000 attendees from more than 105 countries expected. The symposium runs in partnership with the American Association for Cancer Research; English is the official language. Attendees can also access the virtual meeting.